Education
About Us
Working with TipRanks
Follow Us
10X Genomics (TXG)
:TXG
TXG Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.78 - $24.38
Previous CloseN/A
Volume385.49K
Average Volume (3M)2.80M
Market Cap
$1.60B
Enterprise Value$1.08B
Total Cash (Recent Filing)$447.26M
Total Debt (Recent Filing)$86.74M
Price to Earnings (P/E)―
Beta1.62
Next Earnings
Oct 29, 2025EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.28
Shares Outstanding114,411,470
10 Day Avg. Volume2,444,359
30 Day Avg. Volume2,804,360
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.68
Enterprise Value/Revenue1.68
Enterprise Value/Gross Profit2.41
Enterprise Value/Ebitda-19.96
Forecast
1Y Price Target
$14.92Price Target Upside16.02% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
Bulls Say, Bears Say
Bulls Say
Acquisition StrategyThe acquisition of Scale Biosciences strengthens 10x Genomics' leadership position in single cell technology.
Revenue And Growth10x Genomics reported 2Q25 results that were above estimates and FactSet consensus, showing optimism for reaccelerating growth.
Technological Leadership10x Genomics has the best offering in single cell with the largest install base and a technological lead vs. competitors.
Bears Say
Budget ConstraintsA significant portion of TXG's revenue comes from the US academic market, which faces budget constraints affecting overall demand.
Capital Expenditure UncertaintyThere is continued caution and uncertainty around capital expenditure visibility due to macroeconomic factors and funding.
Macroeconomic ChallengesThe macro environment remains challenging with external headwinds affecting the biopharma end-market and causing uncertainty in purchasing tools for discovery research.
10x Genomics News
TXG FAQ
What was 10X Genomics’s price range in the past 12 months?
10X Genomics lowest stock price was $6.78 and its highest was $24.38 in the past 12 months.
What is 10X Genomics’s market cap?
10X Genomics’s market cap is $1.60B.
When is 10X Genomics’s upcoming earnings report date?
10X Genomics’s upcoming earnings report date is Oct 29, 2025 which is in 41 days.
How were 10X Genomics’s earnings last quarter?
10X Genomics released its earnings results on Aug 07, 2025. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of -$0.37 by $0.65.
Is 10X Genomics overvalued?
According to Wall Street analysts 10X Genomics’s price is currently Undervalued.
Does 10X Genomics pay dividends?
10X Genomics does not currently pay dividends.
What is 10X Genomics’s EPS estimate?
10X Genomics’s EPS estimate is -0.29.
How many shares outstanding does 10X Genomics have?
10X Genomics has 114,411,470 shares outstanding.
What happened to 10X Genomics’s price movement after its last earnings report?
10X Genomics reported an EPS of $0.28 in its last earnings report, beating expectations of -$0.37. Following the earnings report the stock price went down -3.984%.
Which hedge fund is a major shareholder of 10X Genomics?
Currently, no hedge funds are holding shares in TXG
10x Genomics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.92 (16.02% Upside)
$14.92 (16.02% Upside)
Blogger Sentiment
Neutral
TXG Sentiment 50%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 3.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $539.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-39.93%
12-Months-Change
Fundamentals
Return on Equity
-11.30%
Trailing 12-Months
Asset Growth
5.41%
Trailing 12-Months
Company Description
10X Genomics
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
TXG Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted a mix of positive developments, such as a favorable litigation settlement and growth in spatial consumables, alongside challenges like declining instrument revenue and a difficult funding environment. While there are areas of growth and strategic advancements, the ongoing challenges in the academic and CapEx environment present significant hurdles.View all TXG earnings summariesTXG Revenue Breakdown
60.32% Americas
22.99% EMEA
8.45% Asia-Pacific excluding China
8.24% China
TXG Stock 12 Month Forecast
Average Price Target
$14.92
▲(16.02% Upside)
Technical Analysis
Omnicell
―
Schrodinger
―
GeneDx Holdings
―
SOPHiA GENETICS
―
Hinge Health, Inc. Class A
―
Ownership Overview
2.31% Insiders
18.28% Mutual Funds
39.56% Other Institutional Investors
11.33% Public Companies and Individual Investors